Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 19/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270235 | 1.00 | GCK (0.52) | GCKNR1H4RARGKCNH2RARA | |
| SCHEMBL2724942 | 0.91 | GCK (0.47) | GCKRARGKCNH2 | |
| SCHEMBL1271326 | 0.85 | NR1H4 (0.43) | GCKNR1H4 | |
| SCHEMBL2732981 | 0.83 | GCK (0.53) | GCKRARGKCNH2 | |
| SCHEMBL2732434 | 0.83 | GCK (0.54) | GCKRARGKCNH2 | |
| SCHEMBL9897401 | 0.82 | GCK (0.51) | GCKKCNH2 | |
| SCHEMBL2724721 | 0.82 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL9898059 | 0.82 | GCK (0.53) | GCKRARGKCNH2 | |
| SCHEMBL9897078 | 0.82 | GCK (0.53) | GCKRARGKCNH2 | |
| SCHEMBL9897930 | 0.82 | GCK (0.70) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | GCK 2/4885NR1H4 2626/4885RARG 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.